Shulman Joseph reported option exercise involving 2,024 shares of RHYTHM PHARMACEUTICALS, INC. at $6.80 for $13.8k on Aug 13, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Technical Officer
Chief Technical Officer
Filed Aug 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$13,763.20Shares × reported price
Shares traded
2,024Common Stock
Price per share
$6.80Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
20,994Direct
Trade date
Aug 13, 2026Option exercise
Filed
Aug 17, 2026, 6:00 PM ET4-day reporting delay
Accession
0001649904-26-000015Code M · Transaction 1075
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 13, 2026Option exercise2,024$0.00$0Trade 1077
Aug 13, 2026Sell5,079$119.75−$608,210.25Trade 1076
3 transaction rows in this filing. Joint filers share the same rows.

RYTM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RYTM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −4.7%1w ago −2.9%1d ago +1.9%
Returns since7d −3.5%30d −15%90d180d1y

Footnotes in full

F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. F2: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.